Your session is about to expire
← Back to Search
Sorafenib + Doxorubicin for Liver Cancer
Study Summary
This trial will test the effect of combining two drugs, sorafenib and doxorubicin, on liver cancer growth and spread.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 40 Patients • NCT01900002Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I am not taking Rifampin or St John's Wort.I have a serious heart condition.I have been treated with doxorubicin through an IV before.I have had another type of cancer before.I have had an organ or bone marrow transplant from a donor.My liver is healthy or only slightly damaged.I am mostly able to care for myself.My liver cancer is confirmed and not a mixed or fibrolamellar type.I've been treated with sorafenib for my cancer, but it has still progressed.My bilirubin levels are low and I don't have a bile duct blockage.I have a history of unusual bleeding.I haven't had bleeding in my esophagus or stomach in the last 30 days.I have fully recovered from any past surgeries or radiation, with the last treatment more than 2 weeks ago.I have had treatments targeting only my liver's cancer, like embolization or radiation.My kidney function is within the normal range.My high blood pressure is well managed with medication.My brain metastases are under control and I don't have seizures.I had radiation therapy for bone pain over two weeks ago.I have active hepatitis B or C but am on treatment, not including interferon.
- Group 1: Sorafenib plus Doxorubicin
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other similar studies has this been compared to?
"As of right now, 438 studies involving the use of Sorafenib are ongoing in 68 countries and 2076 cities. The earliest study on record was completed by Alfacell in 1997 and involved 300 phase 3 drug approval participants. In the 24 years since then, 1067 additional studies have been carried out."
How many different facilities are coordinating this research?
"Currently, this study is being conducted across 6 sites. The facilities are situated in Commack and Rockville Centre, New york as well as other locations. If you enroll in the trial, it would be advantageous to choose a location close to you to limit travel burden."
What are the most common conditions that doctors use Sorafenib to manage?
"Sorafenib is commonly used to treat hodgkins and non-hodgkins lymphoma. This medication can also be effective for treating other rarer cancers including carcinomas, neuroblastomas, and advanced uterine sarcomas."
Are there any life-threatening risks associated with Sorafenib?
"Sorafenib has not been proven effective yet in clinical trials, however it has shown some safety in Phase 2 testing and is thus given a score of 2."
Are there other research projects that have revolved around Sorafenib?
"Currently, 438 different medical studies are actively investigating Sorafenib with 141 of them in Phase 3. The global distribution of these clinical trials is quite extensive, with 26013 locations running studies for Sorafenib. However, the majority of these trials are taking place in Taibei, Taiwan."
Are patients able to join this research trial at this time?
"This specific clinical trial is no longer recruiting patients, but there are other opportunities. This study was first posted on April 1st, 2013 and updated May 2nd, 2022. There are 2766 trials for disease progression and 438 studies involving Sorafenib that are actively recruiting participants."
How many people are eligible for this clinical trial?
"This particular trial is not recruiting patients at the moment. It was initially posted on April 1st, 2013 and updated for the last time on May 2nd, 2022. However, there are 2766 other trials that are actively seeking participants with disease progression and 438 studies for Sorafenib that are enrolling patients right now."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger